Category News

WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder and SAB Chair Dr. Fred Ramsdell on Winning the 2025 Nobel Prize in Physiology or Medicine

WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder Dr. Fred Ramsdell on Receiving the 2025 Nobel Prize in Physiology or Medicine WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulated Fred Ramsdell, PhD, co-founder and Chair…

Read MoreWuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder and SAB Chair Dr. Fred Ramsdell on Winning the 2025 Nobel Prize in Physiology or Medicine

Neurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency

Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…

Read MoreNeurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency

TIME Names LEQEMBI® IQLIK™ Subcutaneous Autoinjector Among 2025’s Best Inventions

LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) today announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector…

Read MoreTIME Names LEQEMBI® IQLIK™ Subcutaneous Autoinjector Among 2025’s Best Inventions

DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss

Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…

Read MoreDB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss

CVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients

CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…

Read MoreCVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients

AstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025

AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…

Read MoreAstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025

FDA Approves Expanded Indication for RINVOQ® (upadacitinib) in the Treatment of Inflammatory Bowel Disease

FDA Approves Updated Indication for AbbVie’s RINVOQ® (upadacitinib) Expanding Access for Patients with Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) updating the indication…

Read MoreFDA Approves Expanded Indication for RINVOQ® (upadacitinib) in the Treatment of Inflammatory Bowel Disease

Innate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025

Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it…

Read MoreInnate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025